The discovery that the vast majority of GISTs have characteristic activating mutations in c-KIT (75–80%) or PDGFRA (5–15%) radically changed the management of these tumours by the approval of the use of tyrosine-kinase inhibitors [4, 15]. Here, PDGFRA is linked to neoplasm.